Phaseline

Targets › GPCD3

GPCD3: drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout May 2041.

Open in Phaseline: the race on GPCD3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zhejiang UniversityC-CAR031
GPC3-targeting armored CAR-T cell therapy
GPCD3Phase 1Hepatocellular CarcinomaMay 2041
Zhejiang UniversityCT0180 Cells
humanized anti-GPC3 CAR-T cell therapy
GPCD3Phase 1Advanced Hepatocellular Carcinoma–

Conditions

Hepatocellular Carcinoma (1) Advanced Hepatocellular Carcinoma (1)

Modalities

mixed (1), other (1)

Companies

Zhejiang University (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.